Logo image of CH.CA

CHARBONE HYDROGEN CORP (CH.CA) Stock Fundamental Analysis

TSX-V:CH - CA15956X1096 - Common Stock

0.055 CAD
0 (-8.33%)
Last: 8/29/2025, 7:00:00 PM
Fundamental Rating

0

CH gets a fundamental rating of 0 out of 10. The analysis compared the fundamentals against 215 industry peers in the Oil, Gas & Consumable Fuels industry. CH has a bad profitability rating. Also its financial health evaluation is rather negative. CH is valued expensive and it does not seem to be growing.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

In the past year CH has reported negative net income.
CH had a negative operating cash flow in the past year.
CH.CA Yearly Net Income VS EBIT VS OCF VS FCFCH.CA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2022 2023 2024 -2M -4M -6M

1.2 Ratios

With a Return On Assets value of -53.33%, CH is not doing good in the industry: 80.84% of the companies in the same industry are doing better.
Industry RankSector Rank
ROA -53.33%
ROE N/A
ROIC N/A
ROA(3y)-94.6%
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
CH.CA Yearly ROA, ROE, ROICCH.CA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2022 2023 2024 0 2K 4K 6K 8K 10K

1.3 Margins

CH does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
CH.CA Yearly Profit, Operating, Gross MarginsCH.CA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2022 2023 2024 -10K -20K -30K

More info and screens

0

2. Health

2.1 Basic Checks

CH does not have a ROIC to compare to the WACC, probably because it is not profitable.
CH has more shares outstanding than it did 1 year ago.
CH has a worse debt/assets ratio than last year.
CH.CA Yearly Shares OutstandingCH.CA Yearly Shares OutstandingYearly Shares Outstanding 2022 2023 2024 20M 40M 60M 80M 100M
CH.CA Yearly Total Debt VS Total AssetsCH.CA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2022 2023 2024 2M 4M 6M

2.2 Solvency

CH has an Altman-Z score of -5.83. This is a bad value and indicates that CH is not financially healthy and even has some risk of bankruptcy.
CH has a Altman-Z score of -5.83. This is in the lower half of the industry: CH underperforms 79.44% of its industry peers.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z -5.83
ROIC/WACCN/A
WACC8.05%
CH.CA Yearly LT Debt VS Equity VS FCFCH.CA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2022 2023 2024 0 2M -2M -4M

2.3 Liquidity

A Current Ratio of 0.03 indicates that CH may have some problems paying its short term obligations.
Looking at the Current ratio, with a value of 0.03, CH is doing worse than 90.65% of the companies in the same industry.
CH has a Quick Ratio of 0.03. This is a bad value and indicates that CH is not financially healthy enough and could expect problems in meeting its short term obligations.
CH has a worse Quick ratio (0.03) than 90.65% of its industry peers.
Industry RankSector Rank
Current Ratio 0.03
Quick Ratio 0.03
CH.CA Yearly Current Assets VS Current LiabilitesCH.CA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2022 2023 2024 1M 2M 3M 4M 5M

More info and screens

1

3. Growth

3.1 Past

CH shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 47.83%, which is quite impressive.
The Revenue has grown by 15.25% in the past year. This is quite good.
EPS 1Y (TTM)47.83%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-75.81%
Revenue 1Y (TTM)15.25%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%-93.75%

3.2 Future

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
CH.CA Yearly Revenue VS EstimatesCH.CA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2022 2023 2024 100K 200K 300K

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

CH reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
CH.CA Price Earnings VS Forward Price EarningsCH.CA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 0 0 0 0 0 0 0 0 0 0

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
CH.CA Per share dataCH.CA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -0.01 -0.02

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A

More info and screens

0

5. Dividend

5.1 Amount

CH does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

CHARBONE HYDROGEN CORP

TSX-V:CH (8/29/2025, 7:00:00 PM)

0.055

0 (-8.33%)

Chartmill FA Rating
GICS SectorEnergy
GICS IndustryGroupEnergy
GICS IndustryOil, Gas & Consumable Fuels
Earnings (Last)N/A N/A
Earnings (Next)N/A N/A
Inst OwnersN/A
Inst Owner ChangeN/A
Ins Owners9.75%
Ins Owner ChangeN/A
Market Cap7.79M
AnalystsN/A
Price TargetN/A
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)N/A
PT rev (3m)N/A
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 31.28
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-0.03
EYN/A
EPS(NY)N/A
Fwd EYN/A
FCF(TTM)-0.01
FCFYN/A
OCF(TTM)-0.01
OCFYN/A
SpS0
BVpS-0.01
TBVpS-0.01
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -53.33%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-94.6%
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score2
Asset Turnover0.04
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 42.12%
Cap/Sales 51.89%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 0.03
Quick Ratio 0.03
Altman-Z -5.83
F-Score2
WACC8.05%
ROIC/WACCN/A
Cap/Depr(3y)222.7%
Cap/Depr(5y)N/A
Cap/Sales(3y)1182.88%
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)47.83%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-75.81%
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)15.25%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%-93.75%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y17.2%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-9.95%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-3.24%
OCF growth 3YN/A
OCF growth 5YN/A